{"preliminary_commentary":{"by_channel":{"youtube":2,"podcast":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["anvumetostat (AMG 193)"],["anvumetostat (AMG 193)","docetaxel"]],"indication":"advanced MTAP-null solid tumors","name":"MTAPESTRY 101","nct_id":"NCT05094336","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mtapestry-101-nct05094336. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MTAPESTRY 101","arms":[{"description":"Participants with MTAP-null solid tumors will receive escalating doses of Anvumetostat to estimate the MTD and/or the RP2D.","label":"Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified MTD/RP2D of Anvumetostat in the following cohort: MTAP-null NSCLC.","label":"Part 1c, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants with MTAP-null NSCLC will receive escalating doses of Anvumetostat + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.","label":"Part 2a, Phase 1: Anvumetostat Dose Exploration + Docetaxel","type":"EXPERIMENTAL"},{"description":"Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of Anvumetostat + docetaxel.","label":"Part 2b, Phase 1: Anvumetostat + Docetaxel Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants with MTAP-null solid tumors will receive Anvumetostat.","label":"Part 3: Anvumetostat Phase 2","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null BTC.","label":"Part 1e, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort:\n\nMTAP-null head and neck squamous cell carcinoma (HNSCC).","label":"Part 1f, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort:\n\nMTAP-null pancreatic adenocarcinoma.","label":"Part 1g, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null or lost MTAP expression solid tumors (other than lymphoma or primary brain tumor).","label":"Part 1h, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive a randomized dose optimization evaluation of Anvumetostat.","label":"Part 1i, Phase 1: Anvumetostat Dose Optimization","type":"EXPERIMENTAL"},{"description":"Participants will receive doses of Anvumetostat and comparator Anvumetostat test tables at different times in a fasted state.","label":"Part 1j, Phase 1: Anvumetostat DSPS Substudy (US Sites Only)","type":"EXPERIMENTAL"},{"description":"Participants will receive Anvumetostat once on a fasted state and once after eating a standardized high-fat, high calorie meal.","label":"Part 1k, Phase 1: Anvumetostat Food Effect Substudy (US Sites Only)","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null esophageal/gastric cancer.","label":"Part 1l, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null glioma.","label":"Part 1m, Phase 1: Anvumetostat Monotherapy Dose Expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"conditions":["Advanced MTAP-null Solid Tumors"],"enrollment":{"count":329,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Anvumetostat","otherNames":["MTA Cooperative PRMT5 inhibitor","AMG 193"],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Comparator Anvumetostat Test Tablet","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-28","lead_sponsor":"Amgen","official_title":"A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-11-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)","timeFrame":"28 days"},{"measure":"Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)","timeFrame":"Up to approximately 3 years"},{"measure":"Part 3: Objective Response Rate (ORR)","timeFrame":"Up to approximately 3 years"}],"references":[],"start_date":{"date":"2022-02-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","url":"https://clinicaltrials.gov/study/NCT05094336"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mtapestry-101-nct05094336"}